Originally from a Greek island, George Asimenos has an undergraduate degree in Electrical and Computer Engineering from the National Technical University of Athens. He then came to sunny California for a PhD in Computer Science at Stanford University, where he got involved in comparative genomics and helped analyze 1% of the human genome as part of the ENCODE Pilot Project. He is currently the Director of Science at D\ NAnexus, a Stanford-spawned startup backed primarily by Google Ventures. Outside of computation biology, he is a cryptography and security enthusiast, and has received the DEFCON Black Badge award.

Julia Bernstein has a passion for using technology to make the healthcare system easier to understand for all stakeholders. She currently drives Strategy and Sales Operations efforts at Ginger.io. Ginger.io's digital mental health platform harnesses passive smartphone data to help patients and support clinicians. Ginger.io has become part of the care solution at institutions such as Kaiser Permanente, Novant Health, a\ nd UCSF. Previously, Julia was a consultant in McKinsey & Co's Boston office, where she focused on healthcare. She also worked for the e-commerce start-up Citrus Lane (acquired by Care.com). She received her AB from Dartmouth College and her MBA from the Stanford Graduate School of Business.

Gourab De, a statistician by training, is part of the Data Science team at Ginger.io, a digital mental health platform that harnesses smartphone data to help patients and support clinicians. His primary focus is statistical analysis of patient-reported and passively gathered smartphone data and its translation into useful insights for healthcare providers. Prior to Ginger.io, Dr. De was part of the Analysis Group's Ne\ w York Office, where his work included pharmaceutical consulting with experience in statistical genetics, clinical trials, retrospective claims analyses, chart review studies, predictive modeling and pharmacoeconomic modeling. He also worked at the Center for Connected Health and NHLBI Candidate Gene Association Resource (CARe), where his research spanned a variety of areas from the relationship between sleep and gene\ tics to medication adherence. Dr. De graduated with honors from the Indian Statistical Institute in Kolkata, India, and received a Ph.D in Biostatistics from Harvard University.

Paul Wallace, MD, is chief medical officer and senior vice president for Clinical Translation. Before joining Optum Labs, Dr. Wallace was senior vice president and director of the Center for Comparative Effectiveness Research (CER) at the Washington DC based Lewin Group. At Lewin, Dr. Wallace and his colleagues supported the use of CER in clinical decision making and policy development. Key projects included the Multi\ payer Claims Database, clinical guideline development and measurement of patient safety in ambulatory care. Dr. Wallace is board vice-chair for AcademyHealth and a board member of the eHealth Initiative. He recently concluded a 6 year term on the Institute of Medicine Board on Population Health and Public Health Practice, and chaired the IOM Committee that produced the 2012 report, ?Primary Care and Public Health: Exploring Integration to Improve Population Health.? He has previously served on the Committee on Performance M\ easurement and Standards Committees for NCQA, the National Advisory Council for AHRQ, the Medical Coverage Advisory Committee for CMS, the Medical Advisory Panel for the Blue Cross and Blue Shield Technology Evaluation Center, as board chair for the Center for Information Therapy, and as a board member and secretary for DMAA: The Care Continuum Alliance. From 1989 to 2011, Dr. Wallace was a medical director and clinician with Kaiser Permanente, where he led initiatives in guideline development, chronic condition care, implementation and use of the electronic health record, and work with employers and policy makers around value realization in health care. He was executive director of Kaiser Permanente?s Care Management Institute from 2000 to 2005. Dr. Wallace?s work has been recognized by the American Medical Informatics Association Nicholas E. Davies CPR Recognition Award of Excellence in 1998, The Improving Chronic Illness Care Program ?Vision Award? in 2004, the Disease Management Association of America Karen Coughlin Individual Disease Management Leadership Award in 2004, and as a Lifetime National Associate of the National Academies of Science in 2011. Dr. Wallace is a graduate of the University of Iowa School of Medicine. He trained in Internal Medicine, Hematology and Cancer Research at the University of Rochester and is Board certified in Internal Medicine and Hematology.

Dr. Vikram (Vik) Bajaj is the lead scientist of Google Life Sciences, where he manages the Baseline Study, the Nanotechnology Program, and other projects. He is also an Associate Professor (consulting) at the Stanford School of Medicine, an Affiliate Scientist of the Lawrence Berkeley National Laboratory and the University of California, Berkeley, for which he serves on the advisory board of the College of Chemistry. Vik's research interests lie at the interface of the physical sciences, engineering, and the life sciences. For example, he and his collaborators have developed nanotechnology probes for the early detection and molecular imaging of disease, spectroscopic tools for imaging objects on the nanoscale, microfabricated and miniaturized analytical and imaging systems for point of care testing, methods and devices which drama\ tically enhance the sensitivity and specificity of MRI, and new tools for clinical bioinformatics. Aspects of this work have been commercialized through Agenea Sciences and SkinScan, where Vik was a founder or co-founder. Vik holds a Ph.D. from the Massachusetts Institute of Technology and was a principal investigator at the University of California, Berkeley, and the Lawrence Berkeley National Laboratory before coming to Google[x]. His scientific and engineering awards include the Anatole Abragam Prize (2012), awarded every three years, the R&D 100 award for the most promising commercialized technologies (in both 2011 and 2013), and t\ he Department of Energy's LBL Innovation Grant (2013). In 2011, he was named as a Visiting Professor of the Chinese Academy of Sciences (young international scientist competition). Vik lives in Mountain View, California; his hobbies include general aviation and sailing.

Patrick Ryan, PhD is Senior Director of Epidemiology and the Head of Epidemiology Analytics at Janssen Research and Development, where he has leading efforts to develop and apply analysis methods to better understand the real-world effects of medical products. He is currently a collaborator in Observational Health Data Sciences and Informatics (OHDSI), a multi-stakeholder, interdisciplinary collaborative to create ope\ n-source solutions that bring out the value of observational health data through large-scale analytics. He served as a principal investigator of the Observational Medical Outcomes Partnership (OMOP), a public-private partnership chaired by the Food and Drug Administration, where he led methodological research to assess the appropriate use of observational health care data to identify and evaluate drug safety issues. \ Patrick received his undergraduate degrees in Computer Science and Operations Research at Cornell University, his Master of Engineering in Operations Research and Industrial Engineering at Cornell, and his PhD in Pharmaceutical Outcomes and Policy from University of North Carolina at Chapel Hill. Patrick has worked in various positions within the pharmaceutical industry at Pfizer and GlaxoSmithKline, and also in acade\ mia at the University of Arizona Arthritis Center.

Jianying Hu is a Principal Research Staff Member and Manager of Healthcare Analytics Research at IBM T. J. Watson Research Center, NY. Prior to joining IBM in 2003 she was with Bell Labs at Murray Hill, New Jersey. Dr. Hu received the Ph.D. degree in Computer Science from SUNY Stony Brook in 1993. Her main research interests include statistical pattern recognition, signal processing, machine learning and data mining,\ with applications to healthcare analytics, medical informatics, business analytics, document analysis, and multimedia content analysis. For the past five years her group has been focusing on developing advanced machine learning, data mining and visual analytics methodologies for deriving data-driven insights to facilitate ?learning health systems?. Dr. Hu has published over 100 technical articles and holds 27 patent\ s. She has served as associate editor for IEEE Transactions on Pattern Analysis and Machine Intelligence, and IEEE Transactions on Image Processing, and is currently on the editorial boards of the journals Pattern Recognition, and International Journal on Document Analysis and Recognition. Dr. Hu is a fellow of IEEE (class of 2015), a fellow of the International Association of Pattern Recognition (class of 2010), and\ a recipient of the Asian American Engineer of the Year Award (class of 2013).

Stephane Budel is a Vice President at DeciBio Consulting, LLC, where he specializes in the analysis of the life science research tools and molecular diagnostics spaces. Dr. Budel's clients and customers include the majority of the top manufacturers in the industry, top management consulting firms, as well as pharmaceutical and diagnostic companies that play or evaluate opportunities in these complex and fluid markets.\ In addition to specializing in evaluating disruptive life science technologies (e.g., next-generation sequencing), he has supported clients facing a broad range of challenging business issues, such as global market opportunity assessment, R&D prioritization, and various business development activities. Over the last decade as a consultant, Dr. Budel built financial models and conducted analyses to support multiple tr\ ansactions leading to merger and acquisition activities in combined excess of $7 billion. He earned his Ph.D. in Physiology from Yale University for his research on the molecular mechanisms of spinal cord injury and schizophrenia.

LinkedIn